Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106872 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
A Phase 1 study of Sarcoma and Soft Tissue Sarcoma, sponsored by Mohammed M Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT01106872: Completed Phase 1 study of Sarcoma and Soft Tissue Sarcoma, sponsored by Mohammed M Milhem.
NCT01106872 is a Phase 1 study of Sarcoma and Soft Tissue Sarcoma that has completed, run by Mohammed M Milhem. The registered enrollment target is 47 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01106872, a Phase 1 study of Sarcoma and Soft Tissue Sarcoma, has completed, sponsored by Mohammed M Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.
Primary Outcome
Dose-limiting toxicities per CTCAE 4.0; grade 4 hematologic toxicity; grade 3 or 4 hepatotoxicity.
Conditions Studied
Interventions
- DRUG Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-08-22 |
| Phase | Phase 1 |
What the finished NCT01106872 record still lists
NCT01106872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid is the first listed.
NCT01106872 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT01106872 about?
NCT01106872 is a clinical study titled "Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas". The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is inv...
What is the current status of trial NCT01106872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-09. Estimated completion is 2017-08-22.
What conditions does trial NCT01106872 study?
This clinical trial studies the following conditions: Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma.
What interventions are being tested in trial NCT01106872?
The interventions under investigation include: Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT01106872?
This trial is sponsored by Mohammed M Milhem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01106872 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01106872's enrollment target sits among peer trials
47 71st of 122 higher than 52 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia